|
 |
Volume 3, Number 6 (June 2006) | |||||
Letter from the Editor |
|||||
325 |
Add your voice to the community dialogue Pennsylvania Hospital, Philadelphia, PA In this issue we focus on two lead articles about gynecologic cancers: Is IP chemotherapy with cisplatin the new standard of care in optimally debulked ovarian cancer patients? A clinical alert recently issued by the NCI seems to suggest that it is. Also: an analysis of early treatment with IL-11 in heavily pretreated patients with gynecologic cancer.
|
||||
Community Dialogue |
|||||
343 |
Reaching the Latino community When Dr. Huerta asks many of his Latino patients whether they know what a Pap smear is, for example, or how prostate cancer might be detected early, more often than not he gets incorrect information. He realized, he said, that people were letting their cancers go out of control because they lacked basic health knowledge. Now on a one-man whirlwind of a campaign, Dr. Huerta is reaching out to the Latino community on radio, television, the Internet—any which way he can to deliver his good health and prevention message.
|
||||
Community Translations |
|||||
348 |
Intraperitoneal therapy for stage III optimally debulked ovarian cancer A recently reported Gynecologic Oncology Group trial showed a remarkable 15.9-month increase in median overall survival for intraperitoneal (IP) versus intravenous chemotherapy among patients with newly diagnosed stage III ovarian cancer or primary peritoneal cancer. These findings raise important questions including whether the benefits of IP treatment can be preserved without excess toxicity. The data are explained, and the issues are discussed.
|
||||
Original Contribution |
|||||
357 |
Early treatment with rhIL-11 in heavily pretreated patients with gynecologic cancer Gynecologic Oncology Specialists of Michigan, Lansing, MI A retrospective chart review of 54 women who had been heavily pretreated for gynecologic cancers suggests that early rhIL-11 treatment during chemotherapy may improve platelet counts at nadir, resulting in fewer interruptions in treatment.
|
||||
Practice Survival |
|||||
372 |
Where faith and medicine meet Campus and Community Ministries of the Christian Medical and Dental Associations, Bristol, TN Giving good medicine makes you a good healer. But offering hope and faith as well may make you an excellent one. The author asks, “What is my responsibility as a doctor toward matters of religious faith among my patients?”
|
||||
Controversies in Patient Management |
|||||
379 |
Prophylactic mastectomy and the clinical management of high-risk breast cancer patients Breast Health Center, Department of Surgery, University of Washington/Seattle Cancer Care Alliance, Seattle, WA Women with a strong family history of breast cancer or BRCA1 or BRCA2 mutations present a clinical management conundrum for surgeons and physicians: When and in which patients is prophylactic mastectomy indicated? It’s critical to re-evaluate patient selection standards and therapeutic options for high-risk patients. Their decision must not be rushed, and should only be made after thorough counseling.
|
||||
Economics/Practice Management |
|||||
385 |
Developing and operating multidisciplinary disease-specific clinics Christiana Care Health Services, Inc., Newark, DE An oncology multidisciplinary clinic (MDC) can raise the standard of care and improve the experience of patients. As a coordinated patient consultation, an MDC provides definitive diagnosis and treatment planning based on the input of an assortment of medical specialists and support services. How to get MDCs up and running to enhance your practice.
|
||||
Implementing Clinical Trials |
|||||
393 |
Community participation in NCI-sponsored clinical trials Community Oncology and Prevention Trials Research Group, National Cancer Institute, Rockville, MD In 2004, the National Cancer Institute spent $800 million on cancer-related clinical trials. Taking part in these trials offers an excellent opportunity for community oncologists and their patients. Here’s how.
|
||||
Letters to the Editor |
|||||
333 |
Why not test the tumor first? Wernersville, PA
|
||||
333 |
Genetic testing and the need for more data Radiation Oncology, Schiffler Cancer Center, Wheeling, WV
|
||||
Brief Communications |
|||||
367 |
Single cutaneous nodule as the first sign of lung cancer: a rare presentation Departments of Radiation Oncology and Pathology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India Case report of a 50-year-old man with a small nodular lesion on his scalp.
|
||||
Legal Matters |
|||||
375 |
Ask your lawyer: working with legal counsel Philadelphia, PA
| ||||
Technology |
|||||
389 |
You’ve got mail Patients are logging on to the Internet to do everything from learning about their disease to e-mailing their doctors and getting virtual second opinions.
| ||||
390 |
Protecting your patients’ e-privacy—and yourself as well Steps you can take now to keep your patients' private mail private.
| ||||
Washington Update |
|||||
397 |
Regulating insurance: who wins and who loses? The latest tussle over insurance legislation pits the American Cancer Society and its supporters against business associations that want to establish national pools under one Federal rule, and not the many mandates of individual states. This time around, the legislation appears to have a better chance of passing in both the House and Senate. And that has the ACS worried that patients will be harmed.
| ||||
On Submitting Articles |
|||||
400 |
Guide for authors
| ||||
© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
65 kb